• Age Related Influence on Screening Coverage and Satisfaction with CervicalCheck

      Fitzpatrick, P; O’Neill, S; Mooney, T; Duignan, A; Flannelly, G (Irish Medical Journal, 2014-07)
    • All Ireland cancer statistics 1994-96 a joint report on incidence and mortality on the island of Ireland

      National Cancer Registry Ireland; Northern Ireland Cancer Registry (National Cancer Registry Ireland and Northern Ireland Cancer Registry, 2001-03)
    • Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.

      Hedden, Lindsay; O'Reilly, Susan; Lohrisch, Caroline; Chia, Stephen; Speers, Caroline; Kovacic, Laurel; Taylor, Suzanne; Peacock, Stuart; Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, V5Z 1L3 Canada. (2012)
      Among women with surgically removed, high-risk HER-2/neu-positive breast cancer, trastuzumab has demonstrated significant improvements in disease-free and overall survival. The objective of this study is to evaluate the cost-effectiveness of the currently recommended 12-month adjuvant protocol of trastuzumab using a Markov modeling approach and real-world cost data.
    • An atlas of cancer in Ireland 1994-2003

      Carsin, Anne-Elie; Sharp, Linda; Comber, Harry (National Cancer Registry, 2009)
    • Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options

      McAnena, Peter F; Brown, James A; Ramli, A.; Curran, C.; Malone, C.; McLaughlin, R.; Barry, K.; JAL, Brown; Kerin, M. J (2018-02-20)
      Abstract Background Recent studies have shown that breast cancer subtype can change from the primary tumour to the recurrence. Discordance between primary and recurrent breast cancer has implications for further treatment and ultimately prognosis. The aim of the study was to determine the rate of change between primary and recurrence of breast cancer and to assess the impact of these changes on survival and potential treatment options. Methods Patient demographics were collected on those who underwent surgery for breast cancer between 2001 and 2014 and had a recurrence with biopsy results and pathology scoring of both the primary and recurrence. Results One hundred thirty two consecutive patients were included. There were 31 (23.5%) changes in subtype. Discordance occurred most frequently in luminal A breast cancer (n = 20), followed by triple negative (n = 4), luminal B (n = 3) and HER2 (n = 3). Patients who changed from luminal A to triple negative (n = 18) had a significantly worse post-recurrence survival (p < 0.05) with overall survival approaching significance (p = 0.064) compared to concordant luminal A cases (n = 46). Overall receptor discordance rates were: estrogen receptor 20.4% (n = 27), progesterone receptor 37.7% (n = 50) and HER2 3% (n = 4). Loss of estrogen receptor and progesterone receptor was more common than gain (21 vs. 6 (p = 0.04) and 44 vs. 6 (p = 0.01) respectively). Nine patients (6.8%) gained receptor status potentially impacting treatment options. Conclusion Discordance in subtype and receptor status occurs between primary and recurrent breast cancer, ultimately affecting survival and potentially impacting treatment options.
    • BreastCheck A decade of screening prior to age-extension

      Mooney, Therese; O’Neill, Sinead; McNally, Sara; Fitzpatrick, Patricia (2015)
    • BreastCheck annual report 2004/2005

      BreastCheck, the National Breast Screening Programme (BreastCheck, the National Breast Screening Programme, 2005-11)
    • BreastCheck programme report 2007/2008

      BreastCheck; National Cancer Screening Service (NCSS) (BreastCheck, 2009)
    • BreastCheck programme report 2008-2009

      BreastCheck; National Cancer Screening Service (NCSS) (BreastCheck, 2010)
    • Breastcheck programme report 2010-2011

      National Cancer Screening Service (NCSS) (National Cancer Screening Service (NCSS), 2012-01)
    • BreastCheck, the National Breast Screening Programme annual report 2005/2006

      BreastCheck, the National Breast Screening Programme (BreastCheck, the National Breast Screening Programme, 2006)
    • BreastCheck: Programme Report 2015 - 2016

      BreastCheck, the National Breast Screening Programme (BreastCheck, the National Breast Screening Programme, 2017-08)
    • Cancer incidence and mortality due to alcohol: An analysis of 10-year data

      Laffoy, M; Mc Carthy, T; Mullen, L; Byrne, D; Martin, J (Irish Medical Journal (IMJ), 2013-12)
    • Cancer research across borders: second report 2001-2002.

      Ireland-Northern Ireland National Cancer Institute Cancer Consortium. (Ireland-Northern Ireland National Cancer Institute., 2002)
    • Cervical check programme report 1 September 2010 – 31 August 2011

      National Cervical Screening Programme (National Cervical Screening Programme, 2012-10)
    • Cervical screening in cases of cervical cancer in Ireland between 2008 - 2018: RCOG Independent Expert Panel Review

      Royal College of Obstetricians and Gynaecologists (RCOG) (Royal College of Obstetricians and Gynaecologists (RCOG), 2019-11)
    • CervicalCheck programme report 2008-2009

      National Cancer Screening Service (NCSS); Health Service Executive (HSE) (National Cancer Screening Service (NCSS), 2010)
    • Change in public awareness of colorectal cancer symptoms following the Be Cancer Alert Campaign in the multi-ethnic population of Malaysia.

      Schliemann, Désirée; Paramasivam, Darishiani; Dahlui, Maznah; Cardwell, Christopher R; Somasundaram, Saunthari; Ibrahim Tamin, Nor Saleha Binti; Donnelly, Conan; Su, Tin Tin; Donnelly, Michael (2020-03-25)
      Background: Colorectal cancer (CRC) cases are detected late in Malaysia similar to most Asian countries. The Be Cancer Alert Campaign (BCAC) was a culturally adapted mass media campaign designed to improve CRC awareness and reduce late detection in Malaysia. The evaluation of the BCAC-CRC aimed to assess campaign reach, campaign impact and health service use. Methods: Participants aged ≥40 years (n = 730) from randomly selected households in Selangor State Malaysia, completed interview-based assessments. Campaign reach was assessed in terms of responses to an adapted questionnaire that was used in evaluations in other countries. The impact of the campaign was assessed in terms of awareness, confidence to detect symptoms and self-efficacy to discuss symptoms with a doctor as captured by the Cancer Awareness Measure (CAM). CAM was administered before-and-after campaign implementation and responses by BCAC recognisers (i.e. participants who recognised one or more of the BCAC television, radio or print advertisements when prompted) and non-recognisers (i.e. participants who did not recognise any of the BCAC advertisements) were compared analytically. Logistic regression analysed comparative differences in cancer awareness by socio-demographic characteristics and recognition of the BCAC materials. Results: Over 65% of participants (n = 484) recognised the BCAC-CRC. Campaign-recognisers were significantly more likely to be aware of each CRC symptom at follow-up and were more confident about noticing symptoms (46.9% vs 34.9%, p = 0.018) compared to non-recognisers. There was no difference between groups in terms of self-efficacy to see a doctor about symptoms. Improved symptoms awareness at follow-up was lower for Indians compared to Malays (adjusted odds ratio (OR) 0.53, 95% Confidence Interval (CI): 0.34, 0.83, p = 0.005). Health service use data did not indicate an increase in screening activity during or immediately after the campaign months. Conclusion: Overall, the findings of the evaluation indicated that the culturally adapted, evidence-based mass media intervention improved CRC symptom awareness among the Malaysian population; and that impact is more likely when a campaign operates a differentiated approach that matches modes of communication to the ethnic and social diversity in a population.
    • Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.

      McAnena, Peter; Tanriverdi, Kahraman; Curran, Catherine; Gilligan, K; Freedman, Jane E; Brown, James A L; Kerin, Michael J (2019-05-10)